Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics. Co.'s clinical programs include: Etrasimod, which Co. is evaluating in a Phase 3 program for ulcerative colitis, a Phase 2b/3 program for Crohn's disease, a Phase 2 program in alopecia areata, and a Phase 2b program for eosinophilic esophagitis; APD418, which is for acute heart failure; Temanogrel, which is in a Phase 2 trial for microvascular obstruction, and a Phase 2 trial for Raynaud's phenomenon secondary to systemic sclerosis; and Olorinab, which Co. is evaluating for a range of visceral pain conditions associated with gastrointestinal diseases. We show 21 historical shares outstanding datapoints in our ARNA shares outstanding history coverage, used to compute ARNA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ARNA market cap history over the course of time is important for investors
interested in comparing ARNA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ARNA versus a peer is one thing; comparing
ARNA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ARNA can fluctuate over the course of history.
With this page we aim to empower investors researching ARNA by allowing them to research the ARNA market cap history. |
Free ARNA Email Alerts:
Video: The Importance of Market Cap
